Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunome Inc IMNM

Healthcare Biotechnology
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its... see more

Recent & Breaking News (NDAQ:IMNM)

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Business Wire 12 days ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Business Wire March 28, 2024

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

GlobeNewswire March 26, 2024

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Business Wire March 26, 2024

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Business Wire March 7, 2024

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Business Wire March 1, 2024

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Business Wire February 20, 2024

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

GlobeNewswire February 20, 2024

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire February 16, 2024

Immunome Announces Pricing of Public Offering of Common Stock

Business Wire February 13, 2024

Immunome Announces Proposed Public Offering of Common Stock

Business Wire February 13, 2024

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

GlobeNewswire February 6, 2024

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Business Wire February 5, 2024

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

Business Wire January 8, 2024

Immunome Appoints Phil Roberts as Chief Technical Officer

Business Wire January 4, 2024

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2024

Immunome Appoints Carol A. Schafer to Board of Directors

Business Wire January 2, 2024

Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

GlobeNewswire December 26, 2023

Immunome to Acquire Antibody-Related Assets and Materials from Atreca

Business Wire December 26, 2023

Immunome to Present at the Stifel 2023 Healthcare Conference

Business Wire November 10, 2023